| Detected | Trial | Change |
|---|---|---|
| 2026-08-07 | NCT07440225 A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) |
Trial sites expanded: 91 -> 97 locations |
| 2026-08-07 | NCT07496567 A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) |
Trial sites expanded: 63 -> 71 locations |
| 2026-07-25 | NCT07440225 A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) |
Trial sites expanded: 87 -> 91 locations |
| 2026-07-25 | NCT07496567 A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) |
Trial sites expanded: 56 -> 63 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2/3 | |||
| NCT07440225 | A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) | Macular Degeneration | Recruiting |
| NCT07496567 | A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) | Macular Degeneration | Recruiting |
| NCT06571045 | A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With… | Diabetic Macular Edema (DME) | Active, Not Recruiting |
| NCT06957080 | A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | Active, Not Recruiting |
| Phase 2 | |||
| NCT07205887 | A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema… | Neovascular Age-Related Macular Degeneration (NVAMD) | Recruiting |
| Phase 1/2 | |||
| NCT06664502 | A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With… | Diabetic Macular Edema (DME) | Active, Not Recruiting |